NASC (Nascent Pharma Holdings) Research & Development: $0.00 Mil (TTM As of Sep. 2024)


NASC Nascent Pharma Holdings Inc NASC
12 GF Score
Price $0.01
View Full Analysis

What is Nascent Pharma Holdings Research & Development?

Nascent Pharma Holdings NASC 12 Research & Development is $0.00 Mil as of Sep. 2024. GuruFocus rates NASC with a GF Score™ of 12/100.

Research & Development is the aggregate amount of research and development expenses during the year. Nascent Pharma Holdings's Research & Development for the three months ended in Sep. 2024 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Nascent Pharma Holdings  (OTCPK:NASC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nascent Pharma Holdings Research & Development Related Terms

Nascent Pharma Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Nascent Pharma Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Pharma Holdings Research & Development Chart

Nascent Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nascent Pharma Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NASC
12GF Score
Nascent Pharma Holdings Inc NASC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nascent Pharma Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Nascent Pharma Holdings (NASC) has a Research & Development of $0.00 Mil as of Sep. 2024. Research and development expense is the total cost for research and development activities. View historical data on Nascent Pharma Holdings and its competitors.
Is Nascent Pharma Holdings' Research & Development too high?
Nascent Pharma Holdings' current Research & Development is $0.00 Mil. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nascent Pharma Holdings' Research & Development compare to ALID and CPMD?
Nascent Pharma Holdings' Research & Development of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nascent Pharma Holdings and its competitors. Nascent Pharma Holdings's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Pharma Holdings stock overvalued right now?
Nascent Pharma Holdings (NASC) has a current Research & Development of $0.00 Mil. The current Research & Development is $0.00 Mil. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current Research & Development is $0.00 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Pharma Holdings Business Description

Address 44 East End Avenue, Hicksville, NY, USA, 11801
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score

Get the complete analysis for NASC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price